RTW Biotech Opportunities Ltd (RTW) ORD NPV
Sell:$1.16
Buy:$1.22
0
Change:
$0.03
(2.52%)
$0.03
(2.52%)
Market closed |
Prices as at close on 25 April 2025
Prices delayed by at least 15 minutes
|
Switch to live prices
|
- Add to watchlist
- Create an alert
- This stock can be held in a
Sell:$1.16
Buy:$1.22
Change:
$0.03
(2.52%)
$0.03
(2.52%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Market closed |
Prices as at close on 25 April 2025
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Sell:$1.16
Buy:$1.22
Change:
$0.03
(2.52%)
$0.03
(2.52%)
Market closed |
Prices as at close on 25 April 2025
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Objective
The Company seeks to achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies. It intends to create a diversiï¬ed portfolio of investments across a range of businesses, each pursuing the development of superior pharmacological or medical therapeutic assets to enhance the quality of life and/or extend patient life.
| Security | Weight |
|---|---|
| HealthCare Inc Shs Stock Settlement | 34.19% |
| Madrigal Pharmaceuticals Inc | 10.48% |
| Cortex Pharmaceuticals, Inc. | 8.48% |
| Akebia Therapeutics Inc | 5.24% |
| Rocket Pharmaceuticals Inc | 4.77% |
| Tarsus Pharmaceuticals Inc Ordinary Shares | 3.51% |
| Avidity Biosciences Inc Ordinary Shares | 1.70% |
| Dyne Therapeutics Inc Ordinary Shares | 0.00% |
| Sector | Weight |
|---|---|
| Financial Services | 34.19% |
| Healthcare | 34.18% |
| Country | Weight |
|---|---|
| United States | 68.37% |
Fee Structure
An annual management fee of 1.25% of the NAV. If the compounded NAV return exceeds 8% p.a., the manager will be entitled to a performance fee of 20%.
Dividend Policy
The Company does not anticipate paying any dividends on its Ordinary Shares, as it intends generally to re-invest proceeds received from Portfolio Company sales or distributions.
ASSET SPLIT
Trust Manager
Not currently available for this investment trust.
Manager Bio
Not currently available for this investment trust.
Board Of Directors
William SimpsonChairman, William Scott, Paul Le Page, Stephanie Sirota, Nicola Blackwood
Data policy - All information should be used for indicative purposes only. You should
independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete,
and accepts no responsibility for how it may be used.
Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.